In Silico Clinical Trials Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2017-2027

Report Description

Global In Silico Clinical Trials market stood at USD2743.64 million in 2021 and is expected to grow at a CAGR of 12.28% during the forecast period on account of factors like growing prevalence of various communicable and non-communicable diseases such as cancer, diabetes, cardiovascular diseases, neurological disorders, SARS-CoV-2 among others requiring different drugs and medical devices for the treatment.

Before the launch of a drug or medical device it is necessary to conduct clinical trials. Clinical Trials are generally time consuming, expensive, harmful for animals, etc. This in turn has led to an increase in demand for solutions which can help in expediting the rate of clinical trials using computational tools, software and platforms which can increase the rate of drug discovery or a new medical device launch, thereby positively influencing the growth of global In Silico Clinical Trials market.

Rapidly Increasing Concerns Over Animal Welfare

The growing concerns related to the harm caused to animals during different types of clinical trials has created a demand for the development of alternative methods for carrying out these trials, thereby supporting the market growth. In January 2020, the US Department of Agriculture had reported that approximately 300,000 animals were involved in pain causing experimental activities in just one year. In silico clinical trials offer an effective way of replacing animal anatomies for conducting various experiments and research & development activities.

Benefits Associated with In Silico Clinical Trials

Numerous benefits associated with In Silico Clinical Trials such as their cost effectiveness in terms of pharmaceutical and therapeutic research, their ability to assess without any significant delays and additional resources thereby increasing their scalability, ensuring animal safety, among others are expected to support the market growth through 2027.

Also, using in silico clinical trials sub population analysis can be done using computational tools by enriching the population segment of interest. Same patient population data can be used for another modality without re-exposing them, leading to a greater scalability.

Sudden Outbreak and Spread of COVID-19 Pandemic

The sudden outbreak and spread of COVID-19 pandemic significantly increased the need and demand for In Silico Clinical Trials since academic & research institutions were shut, the human participation was reduced due to lockdown and social distancing norms, among others.

Also, COVID-19 led to the widespread use of platforms such as Universal Immune System Simulator (UISS) to predict the dynamics of SARS-CoV-2 and related immune system host response. This platform was also used to design effective vaccines based on monoclonal antibodies.

Click here to download the sample

Market Segmentation

The global In Silico Clinical Trials market segmentation is based on industry, therapeutic area, region and company. Regionally, North America dominated the market in 2021 among Europe, Asia Pacific, South America and Middle East & Africa. In North America, the United States dominated the market with an overall share of 77.01% in 2021 on account of increasing use case scenario in the United States such as the testing of mini-invasive total hip replacement known as Proximal Epiphyseal Replacement device designed by Stryker Corporation.

Company Profile

Dassault Systèmes SE, Certara Inc., Insilico Medicine, GNS Healthcare Inc., The AnyLogic Company, Novadiscovery SAS, InSilicoTrials Technologies SpA, Immunetrics Inc, CATO SMS, Evotec SE are some of the major players operating in the global In Silico Clinical Trials market.

Attribute	Details
Market Size value in 2021	USD2743.64 Million
Revenue Forecast in 2027	USD5451.19 Million
United States Market Size Value in 2021	USD853.60 Million
Growth Rate	12.28%
Base Year	2021
Historical Years	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
Report Coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments Covered	Industry Therapeutic Area
Regional Scope	North America; Europe; Asia Pacific; South America; Middle East & Africa
Country Scope	United States; Canada; Mexico; Germany; Italy; United Kingdom; France; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE
Key Companies Profiled	Dassault Systèmes SE, Certara Inc., Insilico Medicine, GNS Healthcare Inc., The AnyLogic Company, Novadiscovery SAS, InSilicoTrials Technologies SpA, Immunetrics Inc, CATO SMS, Evotec SE
Customization Scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request)

Report Scope:

In this report, global In Silico Clinical Trials market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

In Silico Clinical Trials Market, By Industry:

Medical Devices
Pharmaceuticals

In Silico Clinical Trials Market, By Therapeutic Area:

Oncology
Neurology
Cardiology
Infectious Diseases
Orthopedic
Dermatology
Others

In Silico Clinical Trials Market, By Region:

North America

United States
Canada
Mexico

Europe

France
Germany
United Kingdom
Italy
Spain

Asia Pacific

Japan
China
Australia
India
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global In Silico Clinical Trials market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of content

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global In Silico Clinical Trials Market

4. Executive Summary

5. Voice of Customer

5.1. Brand Awareness

5.2. Factors Contributing to Switch to In Silico Clinical Trials

5.3. Demand for In Silico Clinical Trials, By Therapeutic Area

5.4. Preference for In Silico Clinical Trials, By Industry

6. Global In Silico Clinical Trials Market Outlook, 2017-2027F

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Industry (Medical Devices v/s Pharmaceuticals)

6.2.2. By Therapeutic Area (Oncology, Neurology, Cardiology, Infectious Diseases, Orthopedic, Dermatology, Others)

6.2.3. By Region

6.2.4. By Company (2021)

6.3. Product Market Map

6.3.1. By Industry

6.3.2. By Therapeutic Area

6.3.3. By Region

7. North America In Silico Clinical Trials Market Outlook, 2017-2027F

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Industry

7.2.2. By Therapeutic Area

7.2.3. By Country

7.3. North America: Country Analysis

7.3.1. United States In Silico Clinical Trials Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Industry

7.3.1.2.2. By Therapeutic Area

7.3.2. Canada In Silico Clinical Trials Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Industry

7.3.2.2.2. By Therapeutic Area

7.3.3. Mexico In Silico Clinical Trials Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Industry

7.3.3.2.2. By Therapeutic Area

8. Europe In Silico Clinical Trials Market Outlook, 2017-2027F

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Industry

8.2.2. By Therapeutic Area

8.2.3. By Country

8.3. Europe: Country Analysis

8.3.1. France In Silico Clinical Trials Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Industry

8.3.1.2.2. By Therapeutic Area

8.3.2. Germany In Silico Clinical Trials Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Industry

8.3.2.2.2. By Therapeutic Area

8.3.3. United Kingdom In Silico Clinical Trials Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Industry

8.3.3.2.2. By Therapeutic Area

8.3.4. Italy In Silico Clinical Trials Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Industry

8.3.4.2.2. By Therapeutic Area

8.3.5. Spain In Silico Clinical Trials Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Industry

8.3.5.2.2. By Therapeutic Area

9. Asia-Pacific In Silico Clinical Trials Market Outlook, 2017-2027F

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Industry

9.2.2. By Therapeutic Area

9.2.3. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. Japan In Silico Clinical Trials Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Industry

9.3.1.2.2. By Therapeutic Area

9.3.2. China In Silico Clinical Trials Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Industry

9.3.2.2.2. By Therapeutic Area

9.3.3. Australia In Silico Clinical Trials Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Industry

9.3.3.2.2. By Therapeutic Area

9.3.4. India In Silico Clinical Trials Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Industry

9.3.4.2.2. By Therapeutic Area

9.3.5. South Korea In Silico Clinical Trials Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Industry

9.3.5.2.2. By Therapeutic Area

10. South America In Silico Clinical Trials Market Outlook, 2017-2027F

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Industry

10.2.2. By Therapeutic Area

10.2.3. By Country

10.3. South America: Country Analysis

10.3.1. Brazil In Silico Clinical Trials Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Industry

10.3.1.2.2. By Therapeutic Area

10.3.2. Argentina In Silico Clinical Trials Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Industry

10.3.2.2.2. By Therapeutic Area

10.3.3. Colombia In Silico Clinical Trials Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Industry

10.3.3.2.2. By Therapeutic Area

11. Middle East and Africa In Silico Clinical Trials Market Outlook, 2017-2027F

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Industry

11.2.2. By Therapeutic Area

11.2.3. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa In Silico Clinical Trials Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Industry

11.3.1.2.2. By Therapeutic Area

11.3.2. Saudi Arabia In Silico Clinical Trials Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Industry

11.3.2.2.2. By Therapeutic Area

11.3.3. UAE In Silico Clinical Trials Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Industry

11.3.3.2.2. By Therapeutic Area

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends and Developments

14. Competitive Landscape

14.1. Competition Outlook

14.2. Company Profiles

14.2.1. Dassault Systèmes SE

14.2.2. Certara Inc.

14.2.3. Insilico Medicine

14.2.4. GNS Healthcare Inc.

14.2.5. The AnyLogic Company

14.2.6. Novadiscovery SAS

14.2.7. InSilicoTrials Technologies SpA

14.2.8. Immunetrics Inc

14.2.9. CATO SMS

14.2.10. Evotec SE

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Figure 1: Global In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 2: Global In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 3: Global In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 4: Global In Silico Clinical Trials Market Share, By Region, By Value, 2017-2027F

Figure 5: Global In Silico Clinical Trials Market Share, By Company, By Value, 2021

Figure 6: Global In Silico Clinical Trials Market Map, By Industry, Market Size (USD Million) & Growth Rate (%), 2021

Figure 7: Global In Silico Clinical Trials Market Map, By Therapeutic Area, Market Size (USD Million) & Growth Rate (%), 2021

Figure 8: Global In Silico Clinical Trials Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 9: North America In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 10: North America In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 11: North America In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 12: North America In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F

Figure 13: United States In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 14: New Cancer Cases Reported in the United States in 2020, Both Sexes, All Ages

Figure 15: United States In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 16: United States In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 17: Canada In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 18: Percentage of Canadians who Reported being Diagnosed with Diabetes, As of 2020, By Age & Gender

Figure 19: Canada In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 20: Canada In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 21: Mexico In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 22: Number of Registered Clinical Studies in Mexico As of February 2021, By Status

Figure 23: Mexico In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 24: Mexico In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 25: Europe In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 26: Europe In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 27: Europe In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 28: Europe In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F

Figure 29: France In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 30: Percentage of New Cancer Cases in France, Both Sexes, All Ages, 2020

Figure 31: France In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 32: France In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 33: Germany In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 34: Percentage of New Cancer Cases in Germany, Both Sexes, All Ages, 2020

Figure 35: Germany In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 36: Germany In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 37: United Kingdom In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 38: United Kingdom Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)

Figure 39: United Kingdom In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 40: United Kingdom In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 41: Italy In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 42: Number of Individuals Suffering from Diabetes in Italy (In 1,000 People), 2017-2020

Figure 43: Italy In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 44: Italy In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 45: Spain In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 46: Percentage of New Cancer Cases in Spain, By Cancer Site, 2020

Figure 47: Spain In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 48: Spain In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 49: Asia Pacific In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 50: Asia Pacific In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 51: Asia Pacific In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 52: Asia Pacific In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F

Figure 53: Japan In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 54: Japan Research & Development Expenditure As a Percentage of GDP, 2017-2020

Figure 55: Japan In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 56: Japan In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 57: China In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 58: Percentage of New Cancer Cases in China, Both Sexes, All Ages, 2020

Figure 59: China In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 60: China In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 61: Australia In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 62: Australia Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)

Figure 63: Australia In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 64: Australia In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 65: India In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 66: Number of Cases of Cerebral Stroke in Senior Citizens Across India (In Million)

Figure 67: India In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 68: India In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 69: South Korea In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 70: Percentage of New Cancer Cases in South Korea, Both Sexes, All Ages, 2020

Figure 71: South Korea In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 72: South Korea In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 73: South America In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 74: South America In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 75: South America In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 76: South America In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F

Figure 77: Brazil In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 78: Brazil Diabetes Estimates in People of Age Group 20-79 Years (In Thousands)

Figure 79: Brazil In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 80: Brazil In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 81: Argentina In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 82: Percentage of New Cancer Cases in South Korea, Both Sexes, All Ages, 2020

Figure 83: Argentina In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 84: Argentina In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 85: Colombia In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 86: Colombia Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)

Figure 87: Colombia In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 88: Colombia In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 89: Middle East & Africa In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 90: Middle East & Africa In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 91: Middle East & Africa In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 92: Middle East & Africa In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F

Figure 93: South Africa In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 94: Percentage of New Cancer Cases in South Africa, Both Sexes, All Ages, 2020

Figure 95: South Africa In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 96: South Africa In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 97: Saudi Arabia In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 98: Saudi Arabia Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)

Figure 99: Saudi Arabia In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 100: Saudi Arabia In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Figure 101: UAE In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F

Figure 102: Percentage of New Cancer Cases in UAE, Both Sexes, All Ages, 2020

Figure 103: UAE In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F

Figure 104: UAE In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F

Frequently asked questions

What will be the scenario of Global In Silico Clinical Trials Market in 2027?

The global In Silico Clinical Trials market is expected to grow at an impressive rate of 12.28% and reach USD5451.19 million in 2027 on account of the growing development of medical devices and drugs which require the use of In Silico Clinical Trials.

What is the scenario of In Silico Clinical Trials Market in Europe Region?

The Europe In Silico Clinical Trials market was valued at USD740.78 million in 2021 and is expected to register a growth of 13.07% during the forecast period. This can be attributed to the growing demand for the service across the region especially in countries like France, Germany, United Kingdom, among others. Additionally, there are various companies based in Europe which are trying to accelerate the development of their platforms in order to make them available to clients across the globe.

Who are the major players operating in the Global In Silico Clinical Trials Market?

Dassault Systèmes SE, Certara Inc., Insilico Medicine, GNS Healthcare Inc., The AnyLogic Company, among others are some of the leading players operating in global In Silico Clinical Trials market.

What are the major factors hampering the growth of Global In Silico Clinical Trials Market?

The major factors impeding the growth of global In Silico Clinical Trials market include lack of awareness, lack of skilled professionals, among others.